Metrics as of 10/17/2026, 06:59 AM (Berlin time), refresh in progress.
Climb Bio Stock
Climb Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Aoife Brennan BCh MMSc
- Employees
- 28
- Market cap
- $564 M
- IPO
- 10/08/2021
- Web
- climbbio.com
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic…
Climb Bio stock: price history
1D
-10.0%
1W
-10.7%
1M
-30.4%
6M
+7.2%
YTD
+145.5%
1Y
+403.6%
2Y
+96.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~11% weaker price swings than usual
Climb Bio stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 16/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Climb Bio Inc is a biopharmaceutical company focused on developing therapeutics to treat inflammatory diseases triggered by autoimmune reactions. The company's primary research asset is the monoclonal antibody Budoprutug, which is being investigated for various indications including systemic lupus erythematosus and membranous nephropathy. As the company is currently in the clinical development phase, its focus is on research and development of new drugs to treat severe autoimmune diseases.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Network effects
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Climb Bio
Analyst assessment of Climb Bio
PRICE TARGET LOW
US$17.00
CONSENSUS
US$28.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 08/09/2026
Climb Bio stock metrics
P/E
-11.83
P/B
3.12
EV/EBITDA
-8.78
RETURN ON EQUITY
-5.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.2%
FLOAT SHARES
51,817,651
AVG. DAILY VOLUME (30D)
1,341,434
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
Thomas Stephen Basil
Attention
Price since yesterday: -10.0%
Search (Google Trends)
Comparable stocks
Frequently asked questions about Climb Bio stock
What does Climb Bio do?
Climb Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Aoife Brennan BCh MMSc, the company employs around 28 people.
The IPO was on 10/08/2021; the stock trades on NASDAQ under the ticker CLYM.
What do analysts say about Climb Bio stock?
7 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$28.00, ranging from US$17.00 to US$40.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Climb Bio report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Climb Bio pay a dividend?
No, Climb Bio currently does not pay a dividend.
Which stocks are comparable to Climb Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Climb Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Climb Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.